Trademark Search in Canada

CRINETICS

View On IC.GC.CA

FORMALIZED

on 1 Sept 2023

Last Applicant/ Owned by

CRINETICS PHARMACEUTICALS INC.

6055 Lusk Blvd.San Diego, CA 92121

Serial Number

2278817 filed on 1^st Sept 2023

Correspondent Address

SMART & BIGGAR LP

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

K1P5Y6

CRINETICS

Trademark usage description

pharmaceutical preparations for modulating neuropeptides and g-protein coupled receptors (gpcrs); pharmaceutical preparations for use in oncology; pha Read More

Classification Information

Class [005]
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders

Classification kind code

Class [042]
Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics

Classification kind code

Mark Details

Serial Number

2278817

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 135 on 10^th Apr 2024	Amendment to Application
Submitted for opposition 287 on 14^th Sept 2023	Pre-Assessment Letter Sent
Submitted for opposition 30 on 1^st Sept 2023	Filed
Submitted for opposition 1 on 1^st Sept 2023	Created
Submitted for opposition 31 on 1^st Sept 2023	Formalized